S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.95 (+2.24%)
AAPL   160.39 (+2.28%)
MSFT   337.30 (+2.31%)
FB   335.70 (+0.77%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.29 (+5.30%)
NVDA   334.60 (+6.21%)
BABA   131.80 (-1.16%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.20 (+4.77%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.20 (-3.33%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.95 (+2.24%)
AAPL   160.39 (+2.28%)
MSFT   337.30 (+2.31%)
FB   335.70 (+0.77%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.29 (+5.30%)
NVDA   334.60 (+6.21%)
BABA   131.80 (-1.16%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.20 (+4.77%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.20 (-3.33%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.95 (+2.24%)
AAPL   160.39 (+2.28%)
MSFT   337.30 (+2.31%)
FB   335.70 (+0.77%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.29 (+5.30%)
NVDA   334.60 (+6.21%)
BABA   131.80 (-1.16%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.20 (+4.77%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.20 (-3.33%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.95 (+2.24%)
AAPL   160.39 (+2.28%)
MSFT   337.30 (+2.31%)
FB   335.70 (+0.77%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.29 (+5.30%)
NVDA   334.60 (+6.21%)
BABA   131.80 (-1.16%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.20 (+4.77%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.20 (-3.33%)
BA   198.10 (-0.56%)
NASDAQ:TGTX

TG Therapeutics Stock Forecast, Price & News

$23.36
-0.62 (-2.59%)
(As of 11/29/2021 03:59 PM ET)
Add
Compare
Today's Range
$23.29
$24.67
50-Day Range
$23.75
$35.51
52-Week Range
$21.06
$56.74
Volume
23,992 shs
Average Volume
1.38 million shs
Market Capitalization
$3.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.77
30 days | 90 days | 365 days | Advanced Chart
Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


TG Therapeutics logo

About TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
272
Year Founded
N/A

Sales & Book Value

Annual Sales
$150 thousand
Price / Sales
22,031.28
Book Value
$2.20 per share

Profitability

Net Income
$-279.38 million
Net Margins
-7,784.36%
Pretax Margin
-7,784.36%

Debt

Price-To-Earnings

Miscellaneous

Free Float
127,038,000
Market Cap
$3.30 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/01/2022

MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

302nd out of 1,392 stocks

Pharmaceutical Preparations Industry

132nd out of 670 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

Is TG Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics
or view top-rated stocks.

How has TG Therapeutics' stock been impacted by COVID-19?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TGTX shares have increased by 133.4% and is now trading at $23.36.
View which stocks have been most impacted by COVID-19
.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TG Therapeutics
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.09. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to analysts' expectations of $3.23 million. TG Therapeutics had a negative trailing twelve-month return on equity of 82.68% and a negative net margin of 7,784.36%. During the same quarter in the previous year, the firm earned ($0.73) EPS.
View TG Therapeutics' earnings history
.

What price target have analysts set for TGTX?

4 brokers have issued twelve-month target prices for TG Therapeutics' shares. Their forecasts range from $26.00 to $95.00. On average, they expect TG Therapeutics' stock price to reach $68.33 in the next twelve months. This suggests a possible upside of 192.5% from the stock's current price.
View analysts' price targets for TG Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Michael Sean Weiss, Chairman, President & Chief Executive Officer
  • Sean A. Power, Chief Financial Officer, Secretary & Treasurer
  • Owen A. O'Connor, Chief Scientific Officer
  • Adam Waldman, Chief Commercial Officer
  • Jenna A. Bosco, Senior Vice President-Corporate Communications

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.26%), Capital World Investors (2.95%), RA Capital Management L.P. (2.90%), Maverick Capital Ltd. (2.33%), Geode Capital Management LLC (1.63%) and Invesco Ltd. (1.27%). Company insiders that own TG Therapeutics stock include Ra Capital Management, LP, William James Kennedy and Yann Echelard.
View institutional ownership trends for TG Therapeutics
.

Which institutional investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Bridger Management LLC, Panagora Asset Management Inc., Citadel Advisors LLC, Citigroup Inc., and New York State Common Retirement Fund.
View insider buying and selling activity for TG Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TG Therapeutics stock?

TGTX stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Invesco Ltd., 683 Capital Management LLC, BlackRock Inc., Maverick Capital Ltd., Fisher Asset Management LLC, Goldman Sachs Group Inc., and Morgan Stanley.
View insider buying and selling activity for TG Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $23.36.

How much money does TG Therapeutics make?

TG Therapeutics has a market capitalization of $3.30 billion and generates $150 thousand in revenue each year. The biopharmaceutical company earns $-279.38 million in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does TG Therapeutics have?

TG Therapeutics employs 272 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

Where are TG Therapeutics' headquarters?

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at [email protected], or via fax at 212-554-4531.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.